Jeffrey S. Miller, M.D.
University of Minnesota
Deputy Director, Masonic Cancer Center
Director, NK Cell Program
We recently caught up with Katy Razvani, Chief, Section of Cellular Therapy at the Department of Stem Cell transplantation and Cellular Therapy to get an insight into her research ahead of the summit in March. Download the full interview.
Enjoy the following insights into some of the presentations featuring at this year’s summit. See what some Robin Parihar, Karl-Johan Malmberg & Bob Valamehr are presenting on in San Diego.
2017 has been a great year for immunotherapy given the approval of CAR-T as a cancer therapeutic. Successes in 2018 looks to continue, so it is important to gain a focused look on NK cells given they have the greatest potential for a robust, allogeneic development approach which overcomes common safety concerns – experienced by CAR-T and all other cell therapies…download to continue reading
Download to see the full report from this year’s survey
Download to see the full report of the event
Download to see the full report of the survey results
Enjoy the following presentations:
-Memory-Like NK Cells Demonstrate Enhanced Anti-Leukemia Activity in a Xenograft Mouse Model and in Patients with Relapse/Refractory AML
By Rizwan Romee, Assistant Professor, Division of Oncology, Washington University
-oNKord® – The First Allogeneic, “Off-the-Shelf” NK Cell Product in Oncology
By Jan Spanholtz, CSO, Glycostem
-CMV-induced Adaptive NK Cells and IL-15 Tri-Specific Killer Engagers (TriKEs) Mediate Enhanced CD16 Signaling for Targeted Cancer Therapy
By Jeffrey Miller, Professor of Medicine, University of Minnesota